The Trump administration has finalized a major healthcare rule that would end federal Medicaid and Children’s Health Insurance Program (CHIP) funding for gender-affirming medical care for minors, intensifying the national debate over transgender healthcare and the federal government’s role in determining which treatments public insurance programs can cover. The rule is scheduled to take effect on October 13, 2026, although expected legal challenges could delay or prevent its implementation.
The policy was originally proposed in December and attracted nearly 35,000 public comments, approximately 90% of which opposed the change, according to the National Women’s Law Center. If implemented, it would particularly affect transgender young people from lower-income families who rely on Medicaid or CHIP and may have few alternatives for paying for treatment.
Gender-affirming healthcare can involve different forms of treatment depending on a patient’s age and individual circumstances. These can include medical monitoring, puberty blockers and hormone therapy. Surgical procedures can also fall within the broader category, although they are less commonly performed on minors. Under the new rule, children currently receiving medications through Medicaid or CHIP would be provided a transition period of up to six months to taper off treatment.
The administration argues that federal taxpayers should not be required to finance these treatments without what it considers sufficiently reliable evidence of long-term safety and clinical benefit. The Department of Health and Human Services has cited international assessments, including the United Kingdom’s Cass Review, in defending its approach. An HHS spokesperson said federal healthcare spending should prioritize evidence-based treatments intended to protect children’s long-term health.
Medical and civil-rights advocates strongly dispute the administration’s interpretation of the scientific evidence. Critics argue that gender-affirming healthcare is supported by medical evidence and say the new rule substitutes political priorities for individualized medical decision-making. They also contend that the administration selectively emphasized evidence supporting restrictions while overlooking research reaching different conclusions.
The regulation is part of a broader Trump administration effort to restrict access to gender-affirming healthcare. HHS previously proposed preventing healthcare systems receiving Medicare or Medicaid payments from providing such treatments. The department also pursued actions against providers under a little-used federal statute, but a federal judge blocked that enforcement effort in April. Separately, federal employees and their families filed a class-action lawsuit on August 3 challenging the administration’s decision to eliminate insurance coverage for gender-affirming care.
The Medicaid and CHIP rule is therefore likely to become another major legal battleground. Opponents are preparing challenges that could stop it before October. States could also potentially use their own Medicaid funds—without federal reimbursement—to maintain some coverage, while private organizations and mutual-aid networks could attempt to help families cover treatment costs.
Beyond transgender healthcare itself, the dispute raises a larger question about how much authority presidential administrations should exercise over medical treatments financed through federal programs. Critics warn that allowing political officials to determine coverage based on changing administrations could establish a precedent affecting other controversial areas of medicine.
For thousands of families, however, the immediate issue is access. If the rule survives court challenges and takes effect, transgender minors dependent on Medicaid and CHIP could face significantly greater financial and practical barriers to continuing treatment, making the policy one of the Trump administration’s most consequential federal actions affecting transgender healthcare.
